Filing Summary
Entity note: The request identifies Leonabio, Inc., but the supplied Form 10-Q is for Athira Pharma, Inc. (Nasdaq: ATHA). This summary reflects the filing provided, not Leonabio.
Business context and reporting period
Athira is a clinical-stage biopharmaceutical company developing small molecules for neurodegenerative disorders. The filing covers the quarter and six months ended June 30, 2022; it was signed August 15, 2022. The company had no approved products and generated no product revenue.
Its lead candidate, fosgonimeton (ATH-1017), is being developed for Alzheimer’s disease. ATH-1020 entered a Phase 1 trial in 2022.
Key financial metrics
Amounts below are in millions of dollars except per-share data. The company reported no revenue; grant income and investment income partly offset operating expenses.
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Research and development expense | $14.8 | $12.0 | $29.3 | $19.5 |
| General and administrative expense | $8.8 | $4.6 | $17.7 | $7.9 |
| Total operating expenses | $23.6 | $16.6 | $47.0 | $27.4 |
| Grant income (expense) | $(1.3) | $2.6 | $1.0 | $4.4 |
| Other income, net | $0.5 | $0.1 | $0.7 | $0.2 |
| Net loss | $(24.3) | $(14.0) | $(45.3) | $(22.8) |
| Net loss per share | $(0.65) | $(0.38) | $(1.20) | $(0.63) |
| Operating cash used | — | — | $35.2 | $14.6 |
At June 30, 2022, cash and cash equivalents were $95.1 million, short-term investments $157.3 million, and long-term investments $29.8 million, totaling $282.2 million in cash, cash equivalents and investments. Total assets were $292.0 million; total liabilities were $11.4 million, including $2.1 million of operating lease liabilities. The filing reports no borrowings or other financial debt. Stockholders’ equity was $280.6 million and accumulated deficit was $141.2 million.
Six-month investing cash inflow was $19.4 million, primarily reflecting investment maturities; financing cash inflow was $0.5 million, from option exercises. Cash, cash equivalents and restricted cash decreased $15.3 million during the six months. Profitability and operating margins are not meaningful for this pre-revenue company.
Material changes versus prior comparable periods
- Six-month net loss nearly doubled year over year, rising from $22.8 million to $45.3 million; total operating expenses increased 71%.
- Six-month R&D expense increased 50%, driven by fosgonimeton trials and extensions, higher personnel and stock compensation, preclinical work, and the ATH-1020 Phase 1 trial. Q2 fosgonimeton expense declined year over year after ACT-AD completion.
- Six-month G&A expense rose 123%, including higher personnel and stock compensation, litigation and proxy-contest costs, business development, and professional services.
- Grant income fell to $1.0 million for the first half from $4.4 million a year earlier. Q2 2022 included a $1.3 million reversal related to NIH approval requirements.
- Accumulated other comprehensive loss on available-for-sale investments increased to $1.9 million from $0.4 million at year-end 2021, primarily reflecting unrealized investment losses.
- The filing corrected an immaterial prior-period error in six-month 2021 weighted-average shares and loss per share: adjusted loss per share was $(0.63), versus $(0.68) as previously reported. Net loss and equity were unaffected.
Outlook, commentary, risks and unusual items
- Management estimated that $282.2 million of cash, cash equivalents and investments would fund operating expenses and capital expenditures for at least 12 months following the report date. The company expects continued losses and says substantial additional funding will be needed; funding may dilute shareholders or require unfavorable terms.
- ACT-AD’s primary endpoint was not met under the prespecified analysis. A prespecified subgroup analysis suggested a diminished effect when fosgonimeton was combined with acetylcholinesterase inhibitors. Post hoc monotherapy analyses showed numerical improvements in P300 latency and ADAS-Cog11, but these were not statistically significant and do not establish efficacy. A prespecified monotherapy subgroup showed a statistically significant reduction in neurofilament light chain; the filing reports the treatment difference as 6.89 pg/ml (p=0.018). Fosgonimeton was generally well tolerated, with no treatment-related serious adverse events or deaths reported in ACT-AD.
- The Phase 3 LIFT-AD trial was ongoing; management said it was evaluating whether ACT-AD results could inform its optimization. Open-label extensions were extended to permit eligible participants up to 18 months of treatment.
- NIH grant carryforward approval is uncertain. The company had received $1.3 million in excess of amounts then reimbursable; if approval is denied, the amount must be returned. Grant income will be recognized if approvals are granted.
- Material unusual risks include a special committee’s finding that former CEO Leen Kawas altered images in her dissertation and at least four co-authored research papers, and that challenged papers were cited in company communications and applications and certain images appeared in WSU’s exclusively licensed dihexa patent. WSU’s review remained ongoing. The company warns of potential impacts on reputation, intellectual property, grants, and business prospects.
- Securities class actions and shareholder derivative actions remained unresolved. On July 29, 2022, the court dismissed some claims in the consolidated securities case but left certain claims against the company and former CEO; plaintiffs could amend by August 19, 2022. Derivative cases were consolidated and stayed. The company could not estimate a possible loss and recorded no liability.
- Management identified continuing COVID-19, clinical enrollment and trial execution, regulatory, third-party manufacturing, competition, intellectual-property, and financing risks. It also cited potential legal costs and stockholder activism.
- Disclosure controls and procedures were deemed effective at a reasonable assurance level, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is Athira Pharma, Inc., not Leonabio, Inc.
- Review final ACT-AD data and subsequent LIFT-AD updates, including whether subgroup findings affect trial design, target population, or development prospects.
- Track WSU’s research-misconduct review and any implications for the licensed dihexa patent, other intellectual property, grants, or regulatory interactions.
- Check the status and potential financial exposure of securities and derivative litigation, including insurance coverage and legal expenses.
- Monitor NIH approval of grant carryforwards and whether the $1.3 million excess payment must be repaid or can be recognized as income.
- Assess cash burn, investment values, clinical spending, and the timing and terms of any future financing against management’s stated runway estimate.